An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Trial Profile

An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2010

At a glance

  • Drugs Cinacalcet (Primary)
  • Indications Hyperparathyroidism; Parathyroid cancer
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 05 Dec 2006 Status change
    • 18 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top